New Executive Medical Director at Florida Hospital
- FLASCO
- July 13, 2016
- News
Mark A. Socinski, MD, has been appointed Executive Medical Director of the Florida Hospital Cancer Institute. In his role, he will oversee the coordination of clinical cancer services for the Florida Hospital network. He will also be an active member of the Institute’s Thoracic Oncology Program.
Dr. Socinski has spent more than 20 years in academia and brings his expertise to Florida Hospital to advance the progress the Cancer Institute has made in becoming one of our nation’s centers of excellence.
“I am looking forward to working with the physicians, nurses, support staff and administration at Florida Hospital to bring the Cancer Institute a higher level of prominence,” Dr. Socinski said. “Our collective efforts will continue our journey toward becoming a nationally recognized leader in cancer care.”
Dr. Socinski is a thoracic oncology expert from the University of Pittsburgh Medical Center (UPMC) Cancer Pavilion. At UPMC, he served as Professor of Medicine and Cardiovascular Surgery; Director of the Lung Cancer Section for the Division of Hematology and Oncology; Co-director of the Lung Cancer Center of Excellence; and Co-director of the Lung Cancer Program. Prior to joining UPMC, Dr. Socinski was Professor of Medicine at the University of North Carolina Department of Medicine.
He is a member of the American Society of Clinical Oncology, the American College of Physicians, the International Association for the Study of Lung Cancer, and the American College of Chest Physicians. Dr. Socinski received his medical degree as well as a Master’s of Science in Pathology from the University of Vermont College of Medicine. He completed his residency at Beth Israel Deaconess Medical Center in Boston, and completed fellowships at Dana Farber Cancer Institute in Boston and Harvard Medical School. He is board certified in internal medicine and medical oncology.
Dr. Socinski’s research focuses on thoracic cancers, and he has been published extensively in national journals including the Journal of Clinical Oncology, Lancet Oncology, the Annals of Oncology and the Journal of Thoracic Oncology. He is active in clinical trials, spearheading the development of novel therapies for the treatment of thoracic cancers.
